# Merck Animal Health Equine Respiratory Update

IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA, DAVIS SCHOOL OF VETERINARY MEDICINE

## Looking Back To What's Ahead

Case demographics as a 'crystal ball'?

If there's one thing this profession (and pandemic) has taught us, it's reflection. Contemplating what we knew then; what we know now. Thinking about what's ahead and analyzing the data and experiences we've acquired to inform the decisions we make moving forward. Hindsight is 20/20, or so the saying goes. There is not a crystal ball in veterinary medicine (or life) but we have amassed 12 years' worth of trending data to reflect upon and drive insights into seasonal infectious upper respiratory disease incidence. In this issue, we'll draw on the power of reflection to help practitioners anticipate disease challenges during the current fall and upcoming winter season.

There is not a crystal ball in veterinary medicine (or life) but we have amassed 12 years' worth of trending data to reflect upon and drive insights into seasonal infectious upper respiratory disease incidence.



## EHV-4 Likely Disease Candidate this Fall and Winter

Reviewing the previous 12 months of program data (July 2019–June 2020), we see that equine herpesvirus type 4 (EHV-4) comprises a significant portion of disease cases, particularly in the October through December timeframe (Figure 1). EHV-4 cases October to December 2019 represented nearly half (47%) of all positive samples. In March 2020, we also saw a spike in EHV-4 cases.

Since the Biosurveillance Program began in 2008, EHV-4 represents 22% of positive samples in the month of October (Figure 2). This is the highest monthly incidence of any infectious upper respiratory disease over the course of the program's 12-year history. The months of November and December are also in the double digits with 14% and 18% of positive EHV-4 cases, respectively.



Figure 1: Twelve-Month Disease Trends July 2019 to June 2020. A total of 708 samples were submitted from July 2019 to June 2020. Overall, 44% of total samples submitted tested positive for one of the six primary pathogens (EHV-4, S. equi, EIV, ERBV, EHV-1, ERAV). EHV-4 was the most frequently diagnosed.<sup>1</sup>



Figure 2: Seasonal Incidence of Equine Upper Respiratory Disease.<sup>1</sup>

What do we know about EHV-4 that makes it so darn common in the fall months? For one, EHV-4 typically occurs in young horse populations— 48% of cases during the October to December 2019 fall season were in horses 1 to 5 years of age. Additionally, fall often coincides with weaning, sales and travel for youngsters. It's a transitional time of year, including shifting weather patterns—creating a confluence of factors for this and other highly contagious respiratory diseases in vulnerable horse populations.

Age of Horse	No. of Cases
<1 year	9
1-5 years	57
6-10 years	16
11-15 years	7
16-20 years	12
> 20 years	5
MEDIA	N AGE = 3

Table 1: EHV-4 (+) Cases by Age July 2019–June 2020 $^1$ 

## Equine Flu Season Follows Closely Behind

Biosurveillance data shows increased flu incidence beginning in December and running through April. The incidence of equine influenza virus (EIV) has been trending upward since 2008, showing considerable spikes in recent years.<sup>1</sup> Equine influenza was the most common infectious upper respiratory disease of the horse in 2019, with significant increases noted in February, March and again in June.<sup>1,2</sup> A recently published study from the Biosurveillance Program documenting upper respiratory tract infections from March 2008 through February 2019 revealed several key considerations for EIV that may help veterinarians prepare for the upcoming winter season:

- **Season.** Peak EIV occurrence took place in the winter and spring months. (Figure 2, reflects 2008–June 2020 timeframe)
- **Clinical signs.** The most common signs associated with EIV were fever, nasal discharge and cough. Subclinical signs may occur in EIV-vaccinated horses.
- **Age.** Horses between 1 and 9 years old tested positive for EIV most often.
- **Use.** Competition horses accounted for 42.1% of positive EIV cases followed closely by pleasure horses at 37.9%.
- **Transport.** Horses with a history of recent transport were more likely to test positive for EIV.
- **Exposure.** Horses living on premises with multiple affected horses were more likely to also become infected.

Through the Biosurveillance Program, we continue to monitor the antigenic drift of EIV. Hemagglutinin (HA) sequencing demonstrates the Florida '13 vaccine strain continues to align extremely well with circulating EIV strains in the field. Ask your Merck Animal Health Equine sales professional to share our recent EIV homology technical bulletin for more information.



## Importance of Herd Immunity

Less transportation and fewer equestrian events due to the COVID-19 pandemic has reduced the risk of infectious disease spread, but it's important to avoid a false sense of security. Pandemic or not, we continue to see a lot of infectious disease in non-traveling horses. Fifty-seven percent of EHV-4, *Streptococcus equi* subspecies *equi* (*S. equi*) and EIV positive cases during the July 2019 to June 2020 timeframe occurred in non-traveling horses. Fifty-nine percent of EHV-4 positive cases had not traveled within the previous 14 days (Table 2). It's important to note that, as with EHV-1, existence of a latent state seriously compromises efforts to control EHV-4 and explains why outbreaks of EHV-1 or EHV-4 can occur in closed populations of horses.

Herd immunity is best achieved by semi-annual EHV (types 1 and 4) and EIV vaccination,<sup>3</sup> whether horses are traveling or staying at home. While EHV-1/4 and EIV vaccines are unable to establish sterile immunity, they are of great benefit in reducing the severity of clinical signs and amount of viral shedding, hence reducing environmental contamination and reducing the risk of EHV and EIV disease spread. In addition, it's important to continue emphasizing the importance of biosecurity and isolation of traveling horses upon their return to the farm.

Demographic	<b>EHV-4</b> (112 cases)	<b>S. equi</b>	EIV
Summary		(78 cases)	(68 cases)
Median Age	3 years	8 years	4 years
	Range: 13 days – 36 years	Range: 4 months – 27 years	Range: 6 months – 24 years
Predominant Breed(s)	Quarter Horse; Thoroughbred	Quarter Horse	Quarter Horse
Travel	<b>No 59%</b>	<b>No 60%</b>	<b>No 50%</b>
	Yes 34%	Yes 27%	Yes 40%
	Unknown 7%	Unknown 13%	Unknown 10%
Primary Discipline	Show 47% Pleasure 33% Other/Unknown 20%	Pleasure 29% Show 46% Other/Unknown 24%	Pleasure 37% Show 43% Other/Unknown 21%

Table 2: Summary of primary demographic parameters for the three major pathogens (July 2019–June 2020).<sup>1</sup> At least 50% of horses testing positive for one of the three major pathogens had not traveled within the past 14 days. We continue to see a higher incidence of disease in non-traveling horses across the major respiratory pathogens. This reinforces the importance of including the resident herd that does not travel in vaccination programs.<sup>3</sup>



Figure 3: Geographic representation of the top three pathogens July 2019–June 2020.<sup>1</sup> Pie represents the proportion of total positive EHV-4, S. equi and EIV cases in an area. Areas of disease overlap are also represented (e.g. cases of EHV-4 and EIV).



## **Case Signalment Matters**

Each Equine Respiratory Update newsletter includes a summary of demographic parameters (signalment) for the primary disease pathogens (see Table 2). This important background information, including age, breed, use and travel patterns provides insight to support not only preventive and management measures, but also predilections to disease susceptibility in our horse population.

The future is still the future, but 12 years of data provides strong predictive analytics to help our industry stay on top of infectious upper respiratory disease. *So, please keep completing those respiratory surveillance questionnaires with your sample submissions!* 

			Phone (DC):							
'eterinarian / Clinic:										
ddreec										
Phone (clinic):		Kan idle	der .							
ward.		Phone:								
arse ID:			v: Sex	Breek	1.5					
compation (circle one):	Racine Show Plea	san Brood	ing Other		100					
ample submitted (circl	k): blood nasal evab	other								
accination history (if i	kaowa(c									
Discase	Vaccine product	Data	e vaccinated or eince last done	Number of doors						
P71A11				production of the						
Influenza										
ore many days has the h as the horac been transp ow many other horacs o	torsa been showing signs p sorted during the past 14 d or the premises are showin SICAL SECTS AND SETE New shorted	prior to stamph lays? ng signe? BITY AT HI MUU	E TIME OF TEST							
A reput fore many days has the h last the herese been transp fore many other horace o CLP Naval discharge	toru been showing signs p oerad during the post 14 d in the premises are showin NEAL SEAN AND SEVE New showed	prior to sampli lays? g. signe? RITY AT TH Mild Jama	ing?	ING Array						
K repar low many days has the h last the herese been transp fore many other herese o CLP Nasal discharge Courth	tores been showing signs p sound during the port 14 of on the premises are showin VCAL SECION AND SEVE Near showed If growth State	prine to sampli laye? grigges? RHTY AT TH Mild Bennis Occasional	ing? Modestr Horse	IMG Brown ID:			Age:	Sex:	Breed:	
A upper low many days has the b last the house been transp for many other borner or CLP Nasal discharge Comph Depression; Jothargy	tores been showing signs poend during the poet 14 d on the presentation are showed <b>NAL SECUS AND SEVE</b> New showed Byween New Showed New Showed	print to sampli lays? ag signs? BITT AT TH Mild Dennin Occasional Milds,	ing? Holeser Horse	ING			Age:	Sex:	Breed:	• •
Couple Constant of the set of the constant of the set of the set of the constant of the set of the set of the Couple Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Constant Couple Co	nora bean showing signs poor or the premises are showing strength of the premises are showing strength of the premises are showing Nature showing Nature showing Nature showing Discussion and presents	prior to sampli lays? grigges? RITY AT TH Mid News Occurring Mid, redy mont	Ing?	ID:	me): Racin	g Show Pleasure	Age: Breeding	Sex:	Breed:	
Copy of the set of the	torna been showing eigen j one during the point 14 d of the precision are showing Near showed If growth Near showed Near Near showed Point showed Point showed Point showed Point showed Point shows are pointed to point show and Point shows are shown	prior to sampli lays? ag signs? BITV AT THE Mide Decessor Occursional Mide color source Mide Mide color source Mide	Horse Occup	ID:	me): Racing	g Show Pleasure	Age: Breeding	Sex: Other	Breed:	
A reput low many days has the 1 list the here been training for many other because CIP Vacal discharge Court Pour (2) Four (2) List welling Law a watch	terra been showing eiges j cond during the point 14 d on the precession are showing CLA, SECNG AND SECT New sheared Hyperatic Sector (Condition) New sheared Description (Condition) New sheared New sheared New sheared New sheared	prine to scamplings? ages? agesigne?	Horse Occup Sample	ID:	me): Racin; iircle): bloo	g Show Pleasure sd nasal swab other	Age: Breeding	Sex: Other	Breed:	
A reput lever many days has the bi- lever many other hereas or commany other hereas or CLP Varial discharge Tomes Tomes Town (2) Limb evelling Lever of pagetite	tores here thereing digns period oversidenting the period of di- or the prevention and therein the CAL SECS AND SATE Name theorem of Name American Discriming and the second Discriming and the second Name American Name American	prior to sample tays? aging signed? Mild Mild Remay Chaosianal Mild, and y among bio one kay aff Mild, inclume visible Mild, Mild Mild	Horse Occup Sampl Vaccin	ID: ation (circle o e submitted (c	me): Racing tircle): bloo (if known):	g Show Pleasure d nasal swab other	Age: Breeding	Sex: Other	Breed:	
A reput fore many days has the 1h is the horizon beam many fore many other horizon (IP Natal discharge Dapprosed); (stharge CN) days Form (CP) Linds welling Linds welling Linds welling Linds are file	torea been shorting signs p and during the part H d in the presence are shorted WALSENCE AND SYM Near Annual Near Annual During Symposium Near Annual During Symposium Near Annual During Symposium Near Annual Near Annual Near Annual Near Annual Near Annual	prior to sample tays? ag signed? Mill Mode Note Mill, and sample Mill, and sample Mill Mill Mill Mill	Horse Occup Sample Vaccin	ID: ation (circle o e submitted (c	me): Racin; tircle): bloo (if known):	g Show Pleasure d nasal swab other Vaccine product	Age: Breeding	Sex: Other	Breed:	
Aropa Aropa	tern been dewring eiger yn wraid dewrin dewrin dewrin dewrin a fel prennes aan dewrin Wr 1. SEAN AND SEA Wer dewrol Wyn alwerd Near dewrol Near dewrol	prior to sample tays? agric against Mild Receipt Mild Receipt Mild Receipt Mild Scotte Mild Scotte Mild Scotte	Horse Occup Sampl Vaccin	ID: ation (circle o e submitted (c ation history Disease	me): Racin; zircle): bloo (if known):	g Show Pleasure d nasal swab other Vaccine product last used	Age: Breeding Date vace time since	Sex: Other inated or e last dose	Breed:	]
A reput A reput A reput lar the hear bear trace for many other hears the last the hear bear the last the last the last CN upon Link verifies Link ve	tern bezet denving eigen sond denving the part of the investment and the sensitive and denving the sense of the investment and the sense of the sens	rise to sample lays? geograf. SHTY AT TH Mid Resource Midd, methy annual Midd, methy annual Midd, Midd Midd Midd Midd Midd Midd Mid	Horse Occup Sampl Vaccin	ID:	me): Racin; ;ircle): bloo (if known):	g Show Pleasure ed nasal swab other Vaccine product inst used	Age: Breeding Date vace time since	Sex: Other clinated or e last dose	Breed:	
A seque wave days has the list that the heave been meany other been wave other been wave other been wave other been wave other been wave Touget Depresents tethary Touget Depresents tethary CNS days Toury (2) List weeking List weeking Depresents Touget Depresents Touget Depresents Touget Depresents Touget Depresents Touget Depresents Touget Depresents Depresents Touget Depresents	The best showing signs point of the point of	E prior to sampling (g) (g)(g)(G) 3011Y AT TH Mid Borons Characteristic Midi, and/or sampling Midi, and/or sam	Horse Occup Sampl	ID: ation (circle o e submitted (c ation history Disease EHV1&4 Influenza	ne): Racin; ;ircle): bloo (if known):	g Show Pleasure id nasal swab other Vaccine product last used	Age: Breeding Date vace time since	Sex: Other clast dose	Breed:	
A reput A reput for many days has the base for many days has the bases of the base of the bases of the bases of the bases of the bases of the bases of the the bases of the bases of the bases of the the bases of the bases of the bases of the the bases of the bases of the bases of the the bases of the bases of the bases of the bases of the the bases of the bases of the bases of the bases of the the bases of the bases of the bases of the bases of the the bases of the bases of the bases of the bases of the the bases of the bases of the bases of the bases of the bases of the the bases of the ba	The set here is denoting signer pointed denoting the point is denoting the point of the pointer set denoting the point of the	rise to sample lays? gright? BUTY AT THE Mild Beroug Theorem Mild Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Mild Beroug Sight Sight Mild Beroug Sight	Horse Occup Sampl	ID: ation (circle o e submitted (c ation history) Disease EHV1&4 Influenza	ne): Racin; tirele): bloo (if known):	g Show Pleasure id nasal swab other Vaccine product last used	Age: Breeding Date vace time since	Sex: Other clast dose	Breed:	
A seque to many days has the list the share have more over the share have been more the share have been more that the share have been the share have b	tern been dewing sign per versid daring the jue 14 de in the presence and their term in the presence and their term in the presence and their term in the presence and the With their term in the presence Neur daring the presence of the presence of the presence of the presence of the presence of the presence of the presence of the presence of the presence of the presence of the presen	E prior to sample ing (C) og (dg)ol Mild Mild Romin Comparison Comparison Mild Mild Mild Romin Single Mild Romin Romin Single Mild Romin Romin Single Mild Romin	Horse Occup Sampl	ID: ation (circle o e submitted (c ation history Disease EHV1&4 Influenza S. equi	me): Racin; zirele): bloo (if known):	g Show Pleasure d nasal swab other Vaccine product last used	Age: Breeding Date vace time since	Sex: Other cinated or bast dose	Breed:	

## **Owner Tips**

#### **COVID** presents opportunity for wellness care conversations

The pandemic illustrates just how important biosurveillance and preventive medicine are to human and horse health alike. COVID-19 provides our equine veterinary profession a unique opportunity to discuss the foundational elements of disease prevention, especially vaccination and biosecurity. Horse owners may be more receptive now to learning how vaccinations work and why they're critical. Discussions about handwashing and respiratory transmission have become commonplace, so horse owners may also be more apt to implement basic biosecurity measures.

This notion is supported by data from a recent survey conducted by Amy Grice, VMD, MBA. More than half of equine veterinarians surveyed report their practice finances have not been impacted by COVID-19. Rather than horse owners seeking less veterinary care, the anecdotal evidence points to a shift from competition-related care to wellness care. (For complete survey results, see the Winter issue of *EquiManagement* magazine, coming out in early November 2020, or listen to Dr. Grice discuss highlights on the *EquiManagement* Disease Du Jour podcast, sponsored by Merck Animal Health.)

Our profession can seize this moment to remind horse owners that the need for disease prevention is ever-present and that performance and soundness checks are not a replacement for wellness exams. Delaying or skipping well care can be just as devastating as delaying sick care. All horses should be seen at least annually for preventive care, especially vaccinations. This is true for performance horses and recreational horses alike—pandemic or no pandemic.



#### **Practice Tip**

#### **Nasal Swab Shortage**

Please note, the UC Davis laboratory is currently experiencing a back order on nasal swabs. To manage current supply, only one swab (instead of two) will be sent with sample kits. Please reference proper sampling techniques (below), including importance of adequate contact time (allow swab to soak for 5 to 10 seconds, while gently rotating) to ensure a good sample.

Tips for improving quality of nasal swab samples

- A synthetic swab with a plastic shaft is ideal. Cotton contains pesticide and herbicide residues that act as inhibitors. It is also more difficult to extract cells from cotton. Remember to collect nasal secretions using two (when available), 6-inch rayon swabs.
- Any kind of organic material—such as dirt, especially during dry conditions—may also act as an inhibitor. If the nostril or swab looks dirty, you may need to clean the nostril and collect another sample.
- Sampling from one nostril is sufficient. Insert two swabs (when available) at one time. Remember to allow swabs to soak for 5 to 10 seconds, while gently rotating swabs.
- Nasopharyngeal swabs generally yield better results for EIV and S. *equi*, whereas there is no difference between nasal and nasopharyngeal collection technique in detecting EHV.
- To optimize the sensitivity of the testing procedures used, it is important to sample only those horses that are symptomatic. Criteria for inclusion:
  - a. Unexplained fever (T ≥ 101.5°F) AND one or more of the following signs: depression, nasal discharge, cough or acute onset of neurologic disease. Please refrain from sampling asymptomatic horses or chronic cases. Unless indicated, a maximum of five samples (from symptomatic horses) per location is encouraged. This service should be used as a diagnostic aid and not a screening tool.

All samples should be labeled with date, name of horse and owner. **Also, please complete the sample submission form and questionnaire before submitting.** The information you submit with each sample is critical to helping our industry better understand and manage current and emerging infectious respiratory disease in the horse.







I love the respiratory panel. It is such a great service for our clients and for us to diagnose fevers of unknown origin (FUOs). The panel screens for the major respiratory diseases and the turnaround time is usually very fast. Thank you!

## About the Newsletter

This bi-annual newsletter is being sent to inform the reader about the information generated through the Biosurveillance Program. Merck Animal Health is passionate about this program and is providing this newsletter to customer veterinarians to help them stay up to date on the latest trends and historical information the study has yielded to date. Technical veterinary advice, interpretation and case management support will be provided by Merck Equine Veterinary Professional Services (Drs. Barnett, Vaala, Gaughan, Craig, Bain, Chappell and Schneider) and Nicola Pusterla, DVM, Department of Medicine and Epidemiology, UC Davis.

If you have questions about the program or **to request past issues of the newsletter,** please call our professional services team at (866) 349-3497, or email us at the addresses listed below.

Dr. D. Craig Barnett craig.barnett@merck.com

Dr. Wendy Vaala wendy.vaala@merck.com

Dr. Earl Gaughan earl.gaughan@merck.com

Dr. Bryant Craig bryant.craig@merck.com Dr. Fairfield Bain fairfield.bain@merck.com

Dr. Duane Chappell duane.chappell@merck.com

Dr. Chrissie Schneider chrissie.schneider@merck.com

Dr. Nicola Pusterla npusterla@ucdavis.edu

## **Relevant Supporting Research**

For more information on the latest respiratory disease published research from Merck Animal Health, click on the links below.

- "Prevalence Factors Associated with Equine Influenza Virus Infection in Equids with Upper Respiratory Tract Infection from 2008 to 2019."
   Vaala W, Barnett DC, James K, Chappell D, Craig B, Gaughan E, Bain F, Barnum SM, Pusterla N. AAEP Proceedings. 2019 Vol 65.
- 2) "Prevalence Factors Associated with EHV-2/5 Among Equines with Signs of Upper Respiratory Infection in the US." James, K., Vaala, W., Chappell, D., Barnett, D.C., Gaughan, E., Craig, B., Bain, F., Pusteria, N.ACVIM 2017 Abstract.
- 3) "<u>Prevalence factors associated with equine herpesvirus type 1 infection in equids with upper respiratory tract infection and/or acute onset of neurological signs from 2008 to 2014"</u> Pusterla, N., Mapes, S., Akana, N., Barnett, D.C., Mackenzie, C., Gaughan, E., Craig, B., Chappell, D., Vaala, W. Vet Rec. 2015; doi: 10.1136/vr.103424.
- 4) "<u>Voluntary Surveillance Program for Equine influenza Virus in the United States from 2010</u> to 2013"

Pusterla, N., Kass, P.H., Mapes, S., Wademan, C., Akana, N., Barnett, D.C., Mackenzie, C., Vaala, W. J Vet Intern Med 2015; 29:417-422

- 5) "Surveillance programme for important equine infectious respiratory pathogens in the USA" Pusterla, N., Kass, P.H., Mapes, S., Johnson, C., Barnett, D.C., Vaala, W., et. al. Vet Rec. 2011 July 2;169(1):12. doi: 0.1136/vr.d2157.
- 6) "<u>Voluntary surveillance program for important equine infectious respiratory pathogens in the</u> <u>United States</u>"

Pusterla, N., Kass, P.H., Mapes, S., Johnson, C., Barnett, D.C., Vaala, W., Gutierrez, C., et. al. *AAEP Proceedings* 2010.

## About the Program

Since March of 2008, Merck Animal Health has been conducting an ongoing, voluntary equine biosurveillance program to study the prevalence and epidemiology of relevant viral and bacterial respiratory pathogens. More than 9,400 samples from U.S. equids of all ages, genders and breeds presenting with fever and signs of acute upper respiratory disease and/or acute neurological disease have been collected since the study began. Samples are submitted by participating Merck Animal Health customer clinics and tested via quantitative PCR at the University of California, Davis School of Veterinary Medicine (UC Davis). To be eligible for testing, horses must have an unexplained fever (T ≥ 101.5°F) AND one or more of the following signs: Depression, nasal discharge, cough, and/or acute onset of neurologic disease. The results are then returned to the Merck Animal Health customer within 24 hours and provide invaluable diagnostic and treatment information.

## Four-Fold Purpose:

- To provide a valuable diagnostic tool to participating Merck Animal Health customers to assist in obtaining an accurate and timely diagnosis during an acute respiratory disease outbreak so they can provide optimal treatment, quarantine and vaccination strategies to their clients and patients.
- To provide the horse industry with a better understanding of the prevalence and epidemiology of these respiratory pathogens.
- 3) To identify and monitor the current circulating strains of major equine respiratory pathogens.
- 4) To evaluate the efficacy of current vaccination protocols.





## The Science of Healthier Animals

2 Giralda Farms • Madison, NJ 07940 • merck-animal-health-usa.com • 800-521-5767 Copyright © 2020 Intervet Inc., d/b/a/ Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. US-PRT-201000002

